Development and external validation of a nomogram predicting prognosis of upper tract urothelial carcinoma after radical nephroureterectomy

被引:13
作者
Zeng, Shuxiong [1 ]
Dai, Lihe [1 ]
Yang, Jun [1 ]
Gao, Xiaomin [1 ]
Yu, Xiaowen [2 ]
Ren, Qian [1 ]
Wang, Kaijian [1 ]
Xu, Jinshan [1 ]
Yang, Zeyu [1 ]
Yang, Bo [1 ]
Wang, Huiqing [1 ]
Yang, Qing [1 ]
Ye, Huamao [1 ]
Hou, Jianguo [1 ]
Pan, Yue [3 ]
Zhang, Zhensheng [1 ]
Weng, Zhiliang [3 ]
Sun, Yinghao [1 ]
Xu, Chuanliang [1 ]
机构
[1] Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai, Peoples R China
[2] Second Mil Med Univ, Changhai Hosp, Dept Geriatr, Shanghai, Peoples R China
[3] Wenzhou Med Univ, Clin Inst 1, Dept Urol, Wenzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Nomogram; Predictors; Prognosis; Upper tract urothelial carcinoma; CISPLATIN-INELIGIBLE PATIENTS; ADJUVANT CHEMOTHERAPY; EUROPEAN ASSOCIATION; SINGLE-ARM; SURVIVAL; OUTCOMES; BLADDER; IMPACT; DIFFERENTIATION; MULTICENTER;
D O I
10.1016/j.urolonc.2018.12.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To create multivariable models with readily available clinicopathologic variables for predicting the prognosis of upper tract urothelial carcinomas (UTUC). Patients and methods: We retrospectively analyzed patients diagnosed as UTUC and underwent radical nephroureterectomy in 2 high volumes, tertiary care centers. A total of 445 patients and 227 patients met the inclusion criteria were included for constructing the prediction model and external validation, respectively. Univariable and multivariable Cox regression models were used to analyze independent risk factors, and nomogram and calibration curve were constructed by R project. Results: The median follow-up for the development and external validation cohorts were 33.5 and 32.5 months, respectively. Multivariable analysis detected older age (>= 65 years), with concurrent bladder cancer at diagnosis, with both ureter and renal pelvic tumor, lymphovascular invasion, urothelial carcinoma with divergent differentiation, higher pathological grade and stage, and positive lymph node were significantly associated with poorer outcome of UTUC. The c-index of the nomogram with these above-mentioned independent risk factors to predict the cancer specific survival was 0.74 (95% CI, 0.64-0.84) and 0.73 (95% CI, 0.59-0.87) for the development cohort and external validation cohort, respectively. Conclusions: We developed and externally validated a novel and accurate nomogram with readily available clinicopathological information for predicting the cancer specific survival of UTUC. This nomogram could help clinicians stratify patients with UTUC into different risk groups with distinct prognosis by the total scores obtained from the prediction tool, thus facilitate decision-making and clinical trial designing. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:290.e17 / 290.e24
页数:8
相关论文
共 40 条
  • [1] Preoperative C-Reactive Protein in the Serum: A Prognostic Biomarker for Upper Urinary Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy
    Aziz, Atiqullah
    Rink, Michael
    Gakis, Georgios
    Kluth, Luis A.
    Dechet, Christopher
    Miller, Florian
    Otto, Wolfgang
    Gierth, Michael
    Denzinger, Stefan
    Schwentner, Christian
    Stenzl, Arnulf
    Fisch, Margit
    Burger, Maximilian
    Fritsche, Hans-Martin
    [J]. UROLOGIA INTERNATIONALIS, 2014, 93 (03) : 352 - 360
  • [2] EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
    Babjuk, Marko
    Boehle, Andreas
    Burger, Maximilian
    Capoun, Otakar
    Cohen, Daniel
    Comperat, Eva M.
    Hernandez, Virginia
    Kaasinen, Eero
    Palou, Joan
    Roupret, Morgan
    van Rhijn, Bas W. G.
    Shariat, Shahrokh F.
    Soukup, Viktor
    Sylvester, Richard J.
    Zigeuner, Richard
    [J]. EUROPEAN UROLOGY, 2017, 71 (03) : 447 - 461
  • [3] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    de Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Perini, Rodolfo F.
    Keefe, Stephen M.
    Bajorin, Dean
    Bellmunt, Joaquim
    [J]. LANCET ONCOLOGY, 2017, 18 (11) : 1483 - 1492
  • [4] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
    Balar, Arjun V.
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Loriot, Yohann
    Necchi, Andrea
    Hoffman-Censits, Jean
    Perez-Gracia, Jose Luis
    Dawson, Nancy A.
    van der Heijden, Michiel S.
    Dreicer, Robert
    Srinivas, Sandy
    Retz, Margitta M.
    Joseph, Richard W.
    Drakaki, Alexandra
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Duran, Ignacio
    Shaffer, David R.
    Eigl, Bernhard J.
    Grivas, Petros D.
    Yu, Evan Y.
    Li, Shi
    Kadel, Edward E., III
    Boyd, Zachary
    Bourgon, Richard
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Thastrom, AnnChristine
    Abidoye, Oyewale O.
    Fine, Gregg D.
    Bajorin, Dean F.
    [J]. LANCET, 2017, 389 (10064) : 67 - 76
  • [5] Birtle A, 2018, J UROLOGY, V199, pE213
  • [6] Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival
    Bourgade, Vincent
    Drouin, Sarah J.
    Yates, David R.
    Parra, Jerome
    Bitker, Marc-Olivier
    Cussenot, Olivier
    Roupret, Morgan
    [J]. WORLD JOURNAL OF UROLOGY, 2014, 32 (02) : 475 - 479
  • [7] Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?
    Brown, Gordon A.
    Busby, J. Erik
    Wood, Christopher G.
    Pisters, Louis L.
    Dinney, Colin P. N.
    Swanson, David A.
    Grossman, H. Barton
    Pettaway, Curtis A.
    Munsell, Mark F.
    Kamat, Ashish M.
    Matin, Surena F.
    [J]. BJU INTERNATIONAL, 2006, 98 (06) : 1176 - 1180
  • [8] Validation of the Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor in a Large Cohort of Chinese Patients with Upper Tract Urothelial Carcinoma
    Cao, Zhen-Peng
    Guan, Bao
    Zhao, Guang-Zhi
    Fang, Dong
    Xiong, Geng-Yan
    Li, Xue-Song
    Zhou, Li-Qun
    [J]. CHINESE MEDICAL JOURNAL, 2017, 130 (17) : 2063 - 2068
  • [9] Predicting Clinical Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
    Cha, Eugene K.
    Shariat, Shahrokh F.
    Kormaksson, Matthias
    Novara, Giacomo
    Chromecki, Thomas F.
    Scherr, Douglas S.
    Lotan, Yair
    Raman, Jay D.
    Kassouf, Wassim
    Zigeuner, Richard
    Remzi, Mesut
    Bensalah, Karim
    Weizer, Alon
    Kikuchi, Eiji
    Bolenz, Christian
    Roscigno, Marco
    Koppie, Theresa M.
    Ng, Casey K.
    Fritsche, Hans-Martin
    Matsumoto, Kazumasa
    Walton, Thomas J.
    Ehdaie, Behfar
    Tritschler, Stefan
    Fajkovic, Harun
    Martinez-Salamanca, Juan I.
    Pycha, Armin
    Langner, Cord
    Ficarra, Vincenzo
    Patard, Jean-Jacques
    Montorsi, Francesco
    Wood, Christopher G.
    Karakiewicz, Pierre I.
    Margulis, Vitaly
    [J]. EUROPEAN UROLOGY, 2012, 61 (04) : 818 - 825
  • [10] Sarcomatoid Carcinoma of the Urinary Bladder: The Final Common Pathway of Urothelial Carcinoma Dedifferentiation
    Cheng, Liang
    Zhang, Shaobo
    Alexander, Riley
    MacLennan, Gregory T.
    Hodges, Kurt B.
    Harrison, Beth T.
    Lopez-Beltran, Antonio
    Montironi, Rodolfo
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2011, 35 (05) : E34 - E46